This report describes that
protein kinase C delta (PKCδ) overexpression prevents TRAIL-induced apoptosis in
breast tumor cells; however, the regulatory mechanism(s) involved in this phenomenon is(are) incompletely understood. In this study, we have shown that TRAIL-induced apoptosis was significantly inhibited in PKCδ overexpressing MCF-7 (MCF7/PKCδ) cells. Our data reveal that PKCδ inhibits
caspase-8 activation, a first step in TRAIL-induced apoptosis, thus preventing TRAIL-induced apoptosis. Inhibition of PKCδ using
rottlerin or PKCδ
siRNA reverses the inhibitory effect of PKCδ on
caspase-8 activation leading to TRAIL-induced apoptosis. To determine if caspase-3-induced PKCδ cleavage reverses its inhibition on
caspase-8, we developed stable cell lines that either expresses wild-type PKCδ (MCF-7/cas-3/PKCδ) or
caspase-3 cleavage-resistant PKCδ mutant (MCF-7/cas-3/PKCδ mut) utilizing MCF-7 cells expressing
caspase-3. Cells that overexpress
caspase-3 cleavage-resistant PKCδ mutant (MCF-7/cas-3/PKCδmut) significantly inhibited TRAIL-induced apoptosis when compared to wild-type PKCδ (MCF-7/cas-3/PKCδ) expressing cells. In MCF-7/cas-3/PKCδmut cells, TRAIL-induced
caspase-8 activation was blocked leading to inhibition of apoptosis when compared to wild-type PKCδ (MCF-7/cas-3/PKCδ) expressing cells. Together, these results strongly suggest that overexpression of PKCδ inhibits
caspase-8 activation leading to inhibition of TRAIL-induced apoptosis and its inhibition by
rottlerin,
siRNA, or cleavage by
caspase-3 sensitizes cells to TRAIL-induced apoptosis. Clinically, PKCδ overexpressing
tumors can be treated with a combination of PKCδ inhibitor(s) and TRAIL as a new treatment strategy.